Farallon Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Farallon Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-400,000	Closed	-$7.1M	–	111
2018 Q3	$7.1M	Buy	+400,000	New	+$6.87M	0.04%	87
2013 Q3	–	Sell	-155,000	Closed	-$2.04M	–	88
2013 Q2	$2.04M	Buy	+155,000	New	+$2.09M	0.04%	79

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Farallon Capital Management's ECYT Position: Q4 2018 in Review

Farallon Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 400,000 shares — an estimated $7.1M sold.

Farallon Capital Management first reported a position in ECYT in Q2 2013 and held it in 2 quarters. The position peaked at $7.1M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Farallon Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Farallon Capital Management sold 400,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $7.1M.
Farallon Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
Farallon Capital Management's Endocyte, Inc. Common Stock position peaked at $7.1M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.